Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

US Patent 7651687 · Granted Jan 26, 2010

Estimated economic value: $19,199,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Alkynyl quinazoline compounds2025
Biomarker signature for predicting tumor response to anti-CD200 therapy2023
Tyrosine kinase inhibitor compositions, methods of making and methods of use2021
Biological markers predictive of anti-cancer response to epidermal growth factor2016
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tu2013
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tu2013
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tu2013
Combination cancer therapy2013
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tu2012
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tu2012
Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tu2012
Biological markers predictive of anti-cancer response to epidermal growth factor2012